|

Disitamab vedotin Clinical Trials

15 actively recruiting trials across 2 locations

No change since June 2026

Also known as: Disitamab Vedotin （RC48-ADC), RC-48, RC48, RC48, RC48-ADC, RC48-ADC

Pipeline

Phase 1: 1Phase 2: 7Phase 3: 3Phase 1/2: 2

Top Sponsors

  • RemeGen Co., Ltd.5
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2
  • RenJi Hospital2
  • Zhejiang Cancer Hospital1
  • Shanxi Province Cancer Hospital1

Indications

  • Cancer15
  • Breast Cancer6
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer1
  • Metastatic HER2 Positive Gastroesophageal Junction Cancer1
  • Unresectable Gastric Carcinoma1

Other13 trials

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Phase 2
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/2
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Phase 3
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Phase 2
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Phase 2
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Phase 1
RC48-ADC in HER2-low Advanced Breast Cancer
N/A

Daphne, Alabama1 trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Southern Cancer Center, PC

Phase 1/2

Gilbert, Arizona1 trial

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Banner Gateway Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.